Vancomycin Does NOT Cover Salmonella enterica
No, vancomycin will not provide effective coverage for Salmonella enterica infections. Vancomycin is exclusively active against Gram-positive organisms and has no clinically relevant activity against Gram-negative bacteria like Salmonella.
Why Vancomycin Fails Against Salmonella
Spectrum of Activity Mismatch
The FDA-approved indications for vancomycin are limited to serious infections caused by susceptible Gram-positive organisms, specifically:
- Methicillin-resistant staphylococci
- Enterococci (in combination therapy)
- Streptococci
- Diphtheroids
- Other Gram-positive cocci and bacilli 1
Vancomycin is explicitly not active against Gram-negative bacilli 1. The drug label clearly states that vancomycin "is not active in vitro against gram-negative bacilli, mycobacteria, or fungi" 1.
Mechanism Explains the Gap
Vancomycin's mechanism of action—inhibiting cell wall synthesis by binding to D-alanyl-D-alanine terminals of peptidoglycan precursors—is rendered ineffective against Gram-negative bacteria like Salmonella due to the outer membrane barrier 2, 3. This impermeability barrier prevents vancomycin from reaching its target site in the periplasmic space where peptidoglycan synthesis occurs.
Research confirms that Salmonella enterica possesses intrinsic resistance to vancomycin, with the outer membrane playing the major protective role 2. Even experimental deletion of specific muramyl endopeptidases (like Spr) only sensitizes Salmonella to vancomycin in laboratory conditions but does not make vancomycin a clinically viable option 2.
Appropriate Antibiotics for Salmonella
For Salmonella enterica infections, appropriate empiric choices include:
- Fluoroquinolones (ciprofloxacin, levofloxacin)
- Third-generation cephalosporins (ceftriaxone, cefotaxime)
- Ampicillin (for susceptible strains)
- Trimethoprim-sulfamethoxazole
These agents have documented Gram-negative activity and appropriate tissue penetration for treating invasive Salmonella infections.
Clinical Pitfall to Avoid
Do not use vancomycin empirically when Salmonella or other Gram-negative enteric pathogens are suspected. Guidelines explicitly exclude vancomycin from empiric treatment of intra-abdominal infections unless methicillin-resistant Staphylococcus aureus (MRSA) is specifically suspected 4. The WHO Expert Committee specifically decided to exclude vancomycin from empiric intra-abdominal infection treatment, noting it is "suitable for targeted treatment of methicillin-resistant Staphylococcus aureus infections" but "not an ideal option for empiric treatment" 4.
If you need Gram-positive coverage alongside Gram-negative coverage for polymicrobial infections, combine appropriate Gram-negative agents with targeted Gram-positive coverage rather than relying on vancomycin alone.